NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP tracks the evolution of analyst and market research coverage of ADMA Biologics, Inc. (NASDAQ: ADMA) following allegations of a channel stuffing scheme that allegedly transformed a 3% revenue decline into reported 20% growth. A securities class action has been commenced on behalf of purchasers of ADMA securities between August 9, 2024 and March 25, 2026. Check if you can recover your ADMA investment losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
Culper Research's March 24, 2026 report concluded that ASCENIV revenues declined an estimated 3% in 2025, compared to the +20% growth ADMA reported in SEC filings. The lead plaintiff deadline is August 10, 2026.
Initial Market Optimism Around ASCENIV
ADMA's narrative centered on ASCENIV as a premium immunoglobulin therapy priced at approximately 92.6 million in 2023 to $362.5 million in 2025, a trajectory that attracted significant market attention. The growth story propelled ADMA shares to more than triple over three years, the lawsuit contends.
The Culper Research Reassessment
Culper Research's detailed report upended the growth narrative by alleging:
- ADMA engaged in a de facto channel stuffing scheme, shipping unwanted ASCENIV inventory to distributors to fabricate revenue growth
- Payors treated ASCENIV as functionally identical to standard IVIGs available at a fraction of the price, imposing strict prior authorization requirements and outright denials
- Providers facing reimbursement challenges slowed ordering, leaving distributors with excess inventory
- An undisclosed related party distributor, Genesis BioPharma Services, operated out of ADMA's own corporate headquarters
- Absent channel stuffing, ADMA's 2025 revenues actually declined an estimated 3% rather than growing 20% as reported
- High-level employees at one of ADMA's two largest distributors corroborated the channel stuffing allegations
Why Independent Research Coverage Matters for Shareholders
When independent research contradicts a company's reported financial trajectory by this magnitude, the action claims, it signals that investors relied on materially misleading disclosures. The gap between +20% reported growth and an estimated -3% real growth represents a fundamental disconnect between what shareholders were told and what was allegedly occurring in the distribution channel.
"When analyst expectations are built on incomplete or misleading company disclosures, the resulting corrections can cause significant investor harm. The disparity between ADMA's reported ASCENIV growth and the estimates presented by independent research raises serious questions about the accuracy of disclosures made during the Class Period." -- Joseph E. Levi, Esq.
Speak with an attorney about recovering your ADMA losses or call (212) 363-7500.
LEAD PLAINTIFF DEADLINE: August 10, 2026
About Levi & Korsinsky, LLP
Levi & Korsinsky, LLP, Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered for investors.
Frequently Asked Questions About the ADMA Lawsuit
Q: What specific misstatements does the ADMA lawsuit allege? A: The complaint alleges ADMA made materially false or misleading statements regarding its revenue recognition practices, internal controls, and related party transactions during the Class Period. When independent research revealed the alleged channel stuffing scheme, ADMA shares declined sharply.
Q: When did ADMA Biologics allegedly mislead investors? A: The Class Period runs from August 9, 2024 to March 25, 2026. The alleged fraud was revealed through Culper Research's March 24, 2026 report detailing the channel stuffing allegations.
Q: What do ADMA investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500. No immediate action is required to remain eligible as a class member.
Q: What if I already sold my ADMA shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the Class Period and sold at a loss may still participate.
Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery.
Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
